Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F ™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.

CONCLUSION: The results of this PMS study support the use of GreenGene F™ as safe and efficacious in hemorrhage prevention and treatment of hemophilia A. These results are consistent with the findings from previously published GreenGene F™ studies. PMID: 29215814 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29215814?dopt=Abstract

Source: J Korean Med Sci - December 8, 2017 Category: General Medicine Authors: Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK Tags: J Korean Med Sci Source Type: research

More News: Bleeding | General Medicine | Haemophilia | Hemophilia | Study